Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer

References

• Ruppert AM, Antoine M, Beau-Faller M, et al. Which platform. to support a personalized lung cancer treatment? Bull Cancer 2012;99(5):529-34
   PubMedGoogle Scholar
• Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150(6):1107-20
   PubMed Web of Science ®Google Scholar
• Nan Y, Jin F, Yang S, et al. Discovery of a set of biomarkers of human lung adenocarcinoma through cell-map proteomics and bioinformatics. Med Oncol 2010;27(4):1398-406
   PubMedGoogle Scholar
• Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450(7171):893-8
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29:abstract CRA7506
   Google Scholar
• Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014;32(2):121-8
   PubMed Web of Science ®Google Scholar
• Kao S, Shiau CK, Gu DL, et al. IGDB. NSCLC: integrated genomic database of non-small cell lung cancer. Nucleic Acids Res 2012;40(Database issue):D972-7
   PubMedGoogle Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68(9):3077-80
   PubMed Web of Science ®Google Scholar
• Hall MJ. Conflicted confidence: academic oncologists’ views on multiplex pharmacogenomic testing. J Clin Oncol 2014;32
   Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomize phase 3 trial. Lancet Oncol 2012;13:239-46
   PubMed Web of Science ®Google Scholar
• Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013;24:54-9
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
   PubMed Web of Science ®Google Scholar
• Thongprasert S, Duffield E, Saijo N, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011;6(11):1872-80
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III randomised, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first line treatment for patients with advanced EGFR mutation positive non-small cell lung cancer (OPTIMAL, CTONG-802): a multicentre, open label, randomised phase 3 study. Lancet Oncol 2011;12:735-42
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3(75):75ra26
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2013;18(5):1472-82
   Google Scholar
• Riely GJ, Yu HA, Arcila ME, et al. Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations. J Clin Oncol 2013;31:abstract 8018
   Google Scholar
• Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-101
   PubMed Web of Science ®Google Scholar
• Janne PA, von Pawel J, Cohen RB, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007;25:3936-44
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83
   PubMed Web of Science ®Google Scholar
• Shi YS, Zhang L, Liu X, et al. A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol 2011;29:abstract 7522
   Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38
   PubMed Web of Science ®Google Scholar
• Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 2013;31:3335-41
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01466660
   Google Scholar
• Yang JCH, Sequist LV, Schuler MH, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014;32(5 Suppl):abstract 8004
   Google Scholar
• Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3337-44
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Janne PA, Mok T, et al. Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). J Clin Oncol 2014;32(5 Suppl):abstract 8018
   Google Scholar
• Ellis PM, Liu G, Millward M, et al. NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. J Clin Oncol 2014;32(5 Suppl):abstract 8036
   Google Scholar
• Wakelee H, Soria J, Camidge R, et al. First-in-human evaluation of C0-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Abstract presented at 4th European Lung Cancer Conference; 26 - 29 March 2014; Geneva, Switzerland
   Google Scholar
• Sequist LV, Soria JC, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014;32(5 Suppl):abstract 8010
   Google Scholar
• Ranson M, Pao W, Kim DW. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFR+) and resistance (T790M) mutations in advanced NSCLC The AURA study. J Thorac Oncol 2013;11(Suppl):abstract P1.11
   Google Scholar
• Ranson M, Pao W, Kim DW, et al. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRM+) and resistance (T790M) mutations in advanced NSCLC, [abstract MO21.12]. Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27 – 30 October 2013; Sydney, Australia
   Google Scholar
• Janne PA, Ramalingam SS, Yang JCH, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8009
   Google Scholar
• Dearden SP, Brown H, Cole R, Jenkins S. EGFR T790M mutation testing within a phase I study with AZD9291. J Clin Oncol 2014;32:abstract e19051
   Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101
   PubMed Web of Science ®Google Scholar
• Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-15
   PubMed Web of Science ®Google Scholar
• Pakkala S, Ramalingam SS. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer 2009;1:S17-23
   Google Scholar
• Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15:3484-94
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Gadgeel SM, Dowlati A, et al. A Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol 2012;7(5):856-65
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Lynch TJ Jr, Lara PN Jr, et al. XL647 a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol 2012;7:219-26
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Pietanza MC, Aftab D, et al. EGFR mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J Thorac Oncol 2012;7(2):434-42
   PubMedGoogle Scholar
• Soria JC, Baselga J, Hanna N, et al. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 2013;49:1815-24
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT00743938
   Google Scholar
• Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013;31:abstract 8031
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01449461
   Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from non smokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-33
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF 02341066) in patients with ALK-positive non-small-cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract 2501
   Google Scholar
• Crino L, Kim D, Riely G, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29(Suppl):abstract 7514
   Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Pilotto S, Peretti U, Novello S, et al. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Expert Opin Pharmacother 2013;14(5):597-608
   PubMed Web of Science ®Google Scholar
• Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32(5 Suppl):abstract 8002
   Google Scholar
• Kim S, Kim TM, Kim DW, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013;8:415-22
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, et al. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9
   PubMed Web of Science ®Google Scholar
• Huang D, Kim DW, Kotsakis A, et al. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics 2013;102:157-62
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Scheier B, Burke JM, et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl):abstract 7526
   Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29(15):e443-5
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370(13):1189-97
   PubMed Web of Science ®Google Scholar
• Kim DW, Mehra R, Tan DSW, et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. J Clin Oncol 2014;32(5 Suppl):abstract 8003
   Google Scholar
• Kinoshita K, Asoh K, Furuichi N, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 2012;20:1271-80
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Kiura K, Nishio M, et al. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: updated safety and efficacy results from AF-001JP. J Clin Oncol 2013;31(Suppl):abstract 8033
   Google Scholar
• Gadgeel S, Ou SI, Chiappori AA, et al. A phase I dose escalation study of a new ALK inhibitor, CH542480202, in ALK+ non-small cell lung cancer patients who have failed crizotinib [abstract O16.06]. Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27 - 30 October 2013; Sydney, Australia
   Google Scholar
• Ou SI, Gadgeel S, Chiappori AA, et al. Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer patients in an ongoing phase I/II study (abstract O16.07). Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27 – 30 October 2013; Sydney, Australia
   Google Scholar
• Camidge DR, Bazhenova L, Salgia R, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: updated results. J Clin Oncol 2013;31(Suppl):abstract 8031
   Google Scholar
• Gettinger SN, Bazhenova L, Salgia R, et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8047
   Google Scholar
• Lovly CM, Heuckmann JM, de Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71(14):4920-31
   PubMed Web of Science ®Google Scholar
• Horn LL, Jeffrey R, Infante JR, et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014;32(5 Suppl):abstract 8030
   Google Scholar
• Mori M, Ueno Y, Konagai S, et al. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol Cancer Ther 2014;13(2):329-40
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01401504
   Google Scholar
• Maitland ML, Ou SHI, Tolcher AW, et al. Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. J Clin Oncol 2014;32(5 Suppl):abstract 2624
   Google Scholar
• Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of Genetespib monotherapy in patients with geno4.typically defined advanced non-small cell lung cancer. Clin Cancer Res 2013;19:3068-77
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Goss GD, Andric ZG, et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second line adenocarcinoma (Galaxy-1). J Clin Oncol 2013;31(Suppl):abstract LBA 8007
   Google Scholar
• Pillai RN, Ramalingam SS. Heat shock protein 90 inhibitors in non-small-cell lung cancer. Curr Opin Oncol. 2014;26(2):159-64
   Google Scholar
• Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60
   PubMed Web of Science ®Google Scholar
• Felip E, Carcereny E, Barlesi F, et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer [abstract 4380]. Ann Oncol 2013;23:ix152
   Google Scholar
• Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase I study of ganetespib monotherapy in patients with genotypically defined advanced non small cell lung cancer. Clin Cancer Res 2013;19:3068-77
   PubMed Web of Science ®Google Scholar
• Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013;3:430-43
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62(23):6997-7000
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Hirsh V, Zhang L, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double blind, placebo controlled MISSION study. Ann Oncol 2012;23(Suppl 9):LBA 33 PR
   Google Scholar
• Scagliotti G, Novello S, von Pawel J, et al. Phase II study of carboplatin and paclitaxel alone or with sorafenib in advanced non small-cell lung cancer. J Clin Oncol 2010;28:1835-42
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Eisen T, Santoro A, et al. Sorafenib (S) þ gemcitabine/cisplatin (GC) vs. GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Ann Oncol 2010;21:viii
   Google Scholar
• Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1(1):44-53
   PubMed Web of Science ®Google Scholar
• Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47
   PubMed Web of Science ®Google Scholar
• Gandara DR, Hiret S, Blumenschein GR, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a phase I/Ib trial. J Clin Oncol 2013;31:abstract 8028
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01192165
   Google Scholar
• Kelly K, Leighl NB, Barlesi F, et al. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): a phase I/Ib trial. J Clin Oncol 2013;31:abstract 8027
   Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01336634
   Google Scholar
• Planchard D, Mazieres J, Riely GJ, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013;31:abstract 8009
   Google Scholar
• Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol 2013;8:e41-2
   PubMed Web of Science ®Google Scholar
• Trejo CL, Juan J, Vicent S, et al. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E. Cancer Res 2012;72:3048-59
   Google Scholar
• Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23(1):121-8
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25
   PubMed Web of Science ®Google Scholar
• Xu CX, Zhao L, Yue P, et al. Augmentation of NVP-BEZ235’s anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 2011;12(6):549-55
   PubMed Web of Science ®Google Scholar
• Besse B, Soria J, Gomez-Roca C, et al. A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer. J Clin Oncol 2011;29:abstract 3044
   Google Scholar
• Von Hoff DD, LoRusso P, Tibes R, et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2010;28:abstract 2541
   Google Scholar
• Navab R, Liu J, Seiden-Long I, et al. Co-’BRAF of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 2009;11:1292-300
   PubMedGoogle Scholar
• Ichimura E, Maeshima A, Nakajima T, Nakamura T. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 1996;87(10):1063-9
   PubMedGoogle Scholar
• Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65(4):1479-88
   PubMed Web of Science ®Google Scholar
• Benedettini E, Sholl LM, Peyton M, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010;177(1):415-23
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298-304
   PubMed Web of Science ®Google Scholar
• Bean J, Brennan C, Shih J-Y, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-7
   PubMed Web of Science ®Google Scholar
• Ujiie H, Tomida M, Akiyama H, et al. Serum Hepatocyte Growth Factor and Interleukin-6 Are Effective Prognostic Markers for Non-small Cell Lung Cancer. Anticancer Res 2012;32:3251-8
   PubMedGoogle Scholar
• Hosoda H, Izumi H, Tukada Y, et al. Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients. Ann Thorac Cardiovasc Surg 2012;18(1):1-7
   PubMedGoogle Scholar
• Masago K, Togashi Y, Fujita S, et al. Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Med Oncol 2012;29:1614-21
   PubMedGoogle Scholar
• Han JY, Kim JY, Lee SH, et al. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer 2011;74:293-9
   PubMedGoogle Scholar
• Meetze KA, Boudrow A, Connoly K, et al. Anti-tumor activity of SCH 900105 (AV299), an anti-HGF antibody, in non-small cell lung cancer models. Mol Cancer Ther 2009;8(Suppl 12):abstract C173
   Google Scholar
• Patnaik A, Weiss GJ, Papadopoulos K, et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;abstract 2525
   Google Scholar
• Tan E, Park K, Lim WT, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 2011;abstract 7571
   Google Scholar
• Mok TSK, Park K, Geater SL, et al. A randomized phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in Asian patients (pts) with lung adenocarcinoma (LA) [abstract 1198P]. Ann Oncol 2012;23(Suppl 9):ix391
   Google Scholar
• Giordano S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther 2009;11:448-55
   PubMed Web of Science ®Google Scholar
• Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31(32):4105-14
   PubMed Web of Science ®Google Scholar
• Spigel DR, Edelman MJ, O’Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 2014;32(5 Suppl):abstract 8000
   Google Scholar
• Sequist LV, von Pawel J, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15
   PubMed Web of Science ®Google Scholar
• Hirashima T, Azuma K, Yamamoto N, et al. Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy. J Clin Oncol 2014;32(5 Suppl):abstract 8052
   Google Scholar
• Scagliotti GV, Novello S, Schiller JH, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 2012;13:391-5
   PubMed Web of Science ®Google Scholar
• Azuma K, Yoshioka H, Yamamoto N, et al. Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial. J Clin Oncol 2014;32(5 Suppl):abstract 8044
   Google Scholar
• Hellerstedt BA, Edelman G, Vogelzang NJ, et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012;30:abstract 7514
   Google Scholar
• Reckamp KL, Frankel PH, Mack PC, et al. Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a California Cancer Consortium phase II trial (NCI 9303). J Clin Oncol 2014;32(5 Suppl):abstract 8014
   Google Scholar
• Camidge DR, Ou SHI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8001
   Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70
   PubMed Web of Science ®Google Scholar
• Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012;30(Suppl):abstract 7508
   Google Scholar
• Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinic pathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352-9
   PubMed Web of Science ®Google Scholar
• Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013;8:e43-4
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion positive lung adenocarcinomas. Cancer Discov 2013;3(6):630-5
   PubMed Web of Science ®Google Scholar
• Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012;18:4910-18
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10(1):25-38
   PubMed Web of Science ®Google Scholar
• De Greve J, Moran T, Graas MP, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013;31:abstract 8063
   Google Scholar
• Kelly RJ, Carter CA, Giaccone G. HER2 mutations in non-small-cell lung cancer can be continually targeted. J Clin Oncol 2012;30:3318-19
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT00818441
   Google Scholar
• Kris MG, David Ross Camidge DR, Giaccone G, et al. Results with dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, in a phase II cohort of patients with HER2-mutant or amplified lung cancer [abstract P1.11-032]. Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27–30 October 2013, Sydney, Australia
   Google Scholar
• Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 2013;31:731-7
   PubMed Web of Science ®Google Scholar
• Ware KE, Hinz TK, Kleczko E, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2013;2:e39
   PubMed Web of Science ®Google Scholar
• Metzner T, Bedeir A, Held G, et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. J Invest Dermatol 2011;131:2087-95
   PubMed Web of Science ®Google Scholar
• Li JL, Sainson RC, Oon CE, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011;71:6073-83
   PubMed Web of Science ®Google Scholar
• Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6(6):e20351
   PubMed Web of Science ®Google Scholar
• Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2010;2(62):62ps56
   PubMedGoogle Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2(62):62ra93
   PubMed Web of Science ®Google Scholar
• Hanna NH, Kaiser R, Sullivan RN, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013;31:abstract 8034
   Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15(2):143-55
   PubMed Web of Science ®Google Scholar
• Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 2012;12(2):107-23
   PubMed Web of Science ®Google Scholar
• Chell V, Balmanno K, Little AS, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene 2013;32:3059-70
   PubMed Web of Science ®Google Scholar
• Ramos AH, Dutt A, Mermel C, et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009;8:2042-50
   PubMed Web of Science ®Google Scholar
• Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non–small-cell lung cancer. J Clin Oncol 2008;26(4):650-6
   PubMed Web of Science ®Google Scholar
• Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br Cancer 2009;101:1543-8
   Google Scholar
• Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1(1):78-89
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Di Mirto C, et al. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer 2013;82:171-2
   PubMed Web of Science ®Google Scholar
• Beauchamp EM, Woods BA, Dulak AM, et al. Acquired Resistance to Dasatinib in Lung Cancer Cell Line Conferred by DDR2 Gatekeeper Mutation and NF1 Loss. Mol Cancer Ther 2014;13(2):475-82
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012;12(7):923-37
   PubMed Web of Science ®Google Scholar
• Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011;6:1098-103
   PubMedGoogle Scholar
• Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013;24(11):2875-80
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24(29):4721-30
   PubMed Web of Science ®Google Scholar
• Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137(9):1337-42
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski A, Mitchell P, et al. START: a phase III study of L-BLP25cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 2013;31:abstract 7500
   Google Scholar
• Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011;12(12):1125-33
   PubMed Web of Science ®Google Scholar
• Garcia B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008;14(3):840-6
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30(17):2046-54
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang S, Gong D, et al. Programmed death-1 up regulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7(5):389-95
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Horn L, Antonia SJ, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial [abstract MO18.03]. Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27 - 30 October 2013; Sydney, Australia
   Google Scholar
• Antonia SJ, Grosso JF, Horak CE, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with non-small-cell-lung cancer (NSCLC) treated with nivolumab (ANTI-PD-1; BMS-936558; ONO-4538) [abstract P2.11-035]. Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27 - 30 October 2013; Sydney, Australia
   Google Scholar
• Rizvi N, Antonia SJ, Chow LQM, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558,ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31:abstract 8072
   Google Scholar
• Carbone DP, Socinski MA, Chen AC, et al. A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator’s choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract TPS8128
   Google Scholar
• Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8020
   Google Scholar
• Rizvi NA, Edward B, Garon EB, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2014;32(5 Suppl):abstract 8007
   Google Scholar
• Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10(15):5094-100
   PubMed Web of Science ®Google Scholar
• Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 2012;98:751-5
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
   PubMed Web of Science ®Google Scholar
• Horn L, Herbst RS, Spigel DR, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1) [abstract MO18.01]. Presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer; 27 – 30 October 2013; Sydney, Australia
   Google Scholar
• Powderly JD, Koeppen H, Hodi S, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol 2013;31:abstract 3001
   Google Scholar
• Khleif S. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. Abstract presented at the European Cancer Congress 2013; Amsterdam, The Netherlands; 2013
   Google Scholar
• Smothers F, Hoos A, Langermann S, et al. AMP-224, a fusion protein that targets PD-1. Ann Oncol 2013;24(Suppl 1):i7
   Google Scholar
• Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human, nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 2008;112(4):863-75
   PubMed Web of Science ®Google Scholar
• Sola C, Chanuc F, Thielens A, et al. Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer 2013;1(Suppl 1):P40
   Google Scholar
• Yin Y, Huang X, Lynn KD, et al. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol Res 2013;1(4):256-68
   PubMed Web of Science ®Google Scholar
• Dragnev K, Attili S, Gagua R, et al. A randomized, open-label, phase 2 trial of paclitaxel/carboplatin with or without bavituximab in patients with previously untreated locally advanced or metastatic non-squamous nonsmall-cell lung cancer. Paper presented at Multidisciplinary Symposium in Thoracic Oncology; 6 September 2012; Chicago, IL, USA
   Google Scholar